{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:05:39Z","timestamp":1726495539746},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.leukres.2010.07.041","type":"journal-article","created":{"date-parts":[[2010,8,24]],"date-time":"2010-08-24T08:23:31Z","timestamp":1282638211000},"page":"237-242","source":"Crossref","is-referenced-by-count":4,"title":["Activity of the potent dual Abl\/Src tyrosine kinase inhibitor FB2 against Bcr\u2013Abl positive cell lines in vitro and in vivo"],"prefix":"10.1016","volume":"35","author":[{"given":"Xia","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.07.041_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2010.07.041_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR\u2013ABL story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu Rev Immunol"},{"issue":"23","key":"10.1016\/j.leukres.2010.07.041_bib0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.leukres.2010.07.041_bib0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2010.07.041_bib0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0301-472X(00)00142-9","article-title":"The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for ampli\ufb01cation of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia","volume":"28","author":"Marley","year":"2000","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.leukres.2010.07.041_bib0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.leukres.2010.07.041_bib0035","doi-asserted-by":"crossref","first-page":"669","DOI":"10.5858\/2006-130-669-IROAO","article-title":"Imatinib resistance: obstacles and opportunities","volume":"130","author":"Litzow","year":"2006","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.leukres.2010.07.041_bib0040","first-page":"152","article-title":"Chronic myeloid leukemia in 2006: a perspective","volume":"91","author":"Mauro","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.leukres.2010.07.041_bib0045","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Mechanisms of resistance to Imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.leukres.2010.07.041_bib0050","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical signi\ufb01cance of BCR\u2013ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.leukres.2010.07.041_bib0055","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR\u2013ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.leukres.2010.07.041_bib0060","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"issue":"5682","key":"10.1016\/j.leukres.2010.07.041_bib0065","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.leukres.2010.07.041_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4137\/117739010700200008","article-title":"NS-187(INNO-406), a Bcr\u2013Abl\/Lyn dual tyrosine kinase inhibitor","volume":"2","author":"Niwa","year":"2007","journal-title":"Anal Chem Insights"},{"issue":"3","key":"10.1016\/j.leukres.2010.07.041_bib0075","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10428190802709438","article-title":"Activity of FB2, a novel dual Abl\/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro","volume":"50","author":"Liu","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.leukres.2010.07.041_bib0080","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.leukres.2010.07.041_bib0085","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2010.07.041_bib0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.leukres.2010.07.041_bib0095","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR\u2013ABL phosphorylation in acute lymphoblastic leukemia cell expressing Mr 190,000 BCR\u2013ABL protein by a tyrosine kinase inhibitor (CGP-57148)","volume":"4","author":"Beran","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.leukres.2010.07.041_bib0100","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","article-title":"Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis","volume":"23","author":"Gambacorti-Passerini","year":"1997","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.leukres.2010.07.041_bib0105","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"27","key":"10.1016\/j.leukres.2010.07.041_bib0110","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide(BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"issue":"47","key":"10.1016\/j.leukres.2010.07.041_bib0115","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.leukres.2010.07.041_bib0120","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr\u2013Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2010.07.041_bib0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR\u2013ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.leukres.2010.07.041_bib0130","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2010.07.041_bib0135","first-page":"3984","article-title":"NS-187, a potent and selective dual Bcr\u2013Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimuta","year":"2005","journal-title":"Blood"},{"issue":"7\u20138","key":"10.1016\/j.leukres.2010.07.041_bib0140","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.biocel.2007.01.027","article-title":"Src kinase signaling in leukaemia","volume":"39","author":"Li","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"15","key":"10.1016\/j.leukres.2010.07.041_bib0145","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"Danhauser-Riedl","year":"1996","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.leukres.2010.07.041_bib0150","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1074\/jbc.M110005200","article-title":"Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils","volume":"277","author":"Gardai","year":"2002","journal-title":"J Biol Chem"},{"issue":"45","key":"10.1016\/j.leukres.2010.07.041_bib0155","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.leukres.2010.07.041_bib0160","first-page":"211","article-title":"Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKIs)","volume":"11","author":"Grana","year":"1995","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.leukres.2010.07.041_bib0165","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3835(01)00404-9","article-title":"Taxol-induced cell cycle arrest and apoptosis: dose\u2013response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition","volume":"165","author":"Das","year":"2001","journal-title":"Cancer Lett"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261000384X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261000384X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T02:50:12Z","timestamp":1636253412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261000384X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S014521261000384X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.07.041","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}